TITLE

Upside for Cosmo, Grossing $89M in Santarus Stock Sale

AUTHOR(S)
Sheridan, Cormac
PUB. DATE
May 2013
SOURCE
BioWorld Today;5/15/2013, Vol. 24 Issue 93, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reveals that Cosmo Pharmaceuticals SpA of Lainate, Italy grossed 89.2 million U.S. dollars from a sale of 4.25 million shares of Santarus Inc. stock. It observes that the transaction will enable the already-profitable Cosmo to begin paying dividends to its shareholders. The article also reports that Cosmo originally accepted 6 million Santarus shares in 2008 as partial payment for a licensing deal involving its ulcerative colitis drug Uceris and traveler's diarrhea rifamycin SV.
ACCESSION #
87646727

 

Related Articles

  • Upside for Cosmo, Grossing $89M in Santarus Stock Sale. Sheridan, Cormac // BioWorld International;5/15/2013, Vol. 18 Issue 20, p1 

    The article discusses Cosmo Pharmaceuticals SpA's its sale of Santarus Inc. stock where it grossed 89.2 million U.S. dollars allowing the company to pay dividend to its shareholders. Cosmo disposed of 4.25 million shares with the net proceeds amounting to about 85.9 million U.S. dollars with a...

  • Cosmo Poised for Filings for Ulcerative Colitis Drug. Moran, Nuala // BioWorld International;11/10/2010, Vol. 15 Issue 44, p1 

    This article reports on the plan of Cosmo Pharmaceutical SpA to file drug application in the U.S. and Europe for budesonide MMX in 2011 following its announcement of results of its second pivotal Phase III trial of the drug for the treatment of ulcerative colitis. The study shows that the drug...

  • Uceris for Ulcerative Colitis.  // Monthly Prescribing Reference;Feb2013, Vol. 29 Issue 2, Special section pA-16 

    The article reports on the announcement of Santarus Inc. regarding the approval of Uceris, an extended release tablets, for the treatment of a chronic inflammatory disease ulcerative colitis.

  • New once-daily formulation for ulcerative colitis approved.  // Drug Topics;2/5/2007, Vol. 151 Issue 3, p10 

    The article reports that the U.S. Food and Drug Administration has approved the new formulation developed by Shire PLC called Lialda for the induction of remission in patients with active, mild to moderate ulcerative colitis. The formulation uses MMX technology from Cosmo Pharmaceuticals that...

  • Go with the gut. MILDENBERG, DAVID; MARTIN, CATHY // Business North Carolina;Aug2014, Vol. 34 Issue 8, p42 

    The article discusses the business growth of drug developer, Salix Pharmaceuticals, Ltd., as of August 2014. Topics mentioned include an increase in the company's stocks due to increased profits and sales of its treatments for gastrointestinal diseases, its rank in the publication "Business...

  • Santarus bolsters its sales-rep force. Weinstein, Deborah // Medical Marketing & Media;Mar2013, Vol. 48 Issue 3, p17 

    The article reports on Santarus Inc.'s addition of 85 sales representatives before its launch of Uceris, an ulcerative colitis drug.

  • BioXell's Search for Alternatives Ends in $41M Purchase by Cosmo. Sheridan, Cormac // BioWorld International;11/25/2009, Vol. 14 Issue 47, p1 

    The article reports on the offer of Cosmo Pharmaceuticals SpA to take over BioXell SpA in a cash-and-shares deal amounting to 41 million U.S. dollar. The offer prices the share of BioXell at 7.68 Swiss francs. The said takeover plan boosted the share price of Cosmo. The cash part of the deal...

  • Salix Pharmaceuticals Forms Secondary Entry. JUAN CARLOS ARANCIBIA // Investors Business Daily;7/29/2014, pB01 

    Medical-sector leader

  • Santarus Announces FDA Extension of UCERIS New Drug Application Target Action Date to Jan 16 2013.  // Biomedical Market Newsletter;8/28/2012, Vol. 21, p1 

    The article focuses on the application for the marketing of new drug "UCERIS," a budesonide tablet by Santarus Inc. for ulcerative colitis and informs that the U.S. Food & Drug Administration (FDA) has extended its data for reviewing the application. It also discusses the outcomes of the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics